Clinical trial
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)
NCT07239336 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)
- Lead sponsor
- Chugai Pharmaceutical
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 16, 2025
- Completion date
- December 15, 2027
- Enrollment
- 92 (estimated)
- Sites
- 74
Conditions
As the registry lists them; a condition with its own page is linked.